Quantinuum Inc. (QNT) is a Broomfield, Colorado-based quantum computing company that develops trapped-ion hardware, middleware, and software. Eleven recent, attributable analyst targets were reviewed, spanning roughly $50 to $80 and averaging about $60.60, which rounds to a $60 central target. The Street's posture is broadly bullish — coverage skews to Buy or Overweight ratings with no Sell ratings in the recent set — but the targets tell a more nuanced story.
After the company's third-quarter results, several firms cut targets sharply while keeping bullish ratings. Morgan Stanley's Joseph Moore reiterated Buy and trimmed the target from $62 to $57; JPMorgan's Harlan Sur kept Buy but lowered from $97 to $80; UBS's David Vogt cut from $93 to $50; Jefferies's Kevin Garrigan cut from $85 to $65; and Craig-Hallum's Richard Shannon reduced from $100 to $60. Cantor Fitzgerald moved its target from $90 to $55, while BofA Securities and BTIG carry $50 and $60 targets respectively. The $50-to-$80 range signals that analysts agree on the company's long-term potential but disagree materially on near-term commercialization timing.
As of mid-November 2026, QNT trades near $33.80, down sharply from its 52-week high of $86.79 and only modestly above its 52-week low of $28.31. Reaching $60 would require a gain of about 78%, a very large move that would only retrace a portion of the stock's decline from its post-IPO peak.
The company completed its initial public offering in June 2026, and the shares have traded in a wide range since. Quantinuum reported third-quarter net revenue of $9.1 million, up 233% year over year, and ended the period with roughly $1.9 billion in cash — a meaningful cushion relative to its current operating losses. The company also secured a $100 million award under the U.S. CHIPS Act. These factors provide a foundation, but the stock's negative momentum and heavy losses mean any path toward $60 likely depends on sustained revenue acceleration and clearer evidence of commercial adoption rather than valuation alone.
The 52-week range of $28.31 to $86.79 frames the stock's volatility. The $28.31 low, set in early November 2026, is the nearest key support level; a sustained break below it would signal further downside. On the upside, the $50 area is a notable resistance zone, both because it is a psychological round-number level and because several analyst targets (UBS and BofA Securities at $50, Cantor Fitzgerald at $55) sit just above it. The $60 target therefore implies clearing this $50-to-$55 band first, with no meaningful technical support between the current price and that zone.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may use longer frameworks given the early stage of quantum commercialization. Investors should watch quarterly revenue growth and the pace of commercial bookings, cash burn and any financing activity, the CHIPS Act award's implementation, and further analyst revisions after each earnings report. Macroeconomic conditions, particularly interest-rate expectations, matter for a pre-profit growth name. The next earnings report and any subsequent target changes will be the clearest near-term signposts.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis shift. For a volatile, momentum-sensitive name like QNT, these signals can help traders surface opportunities, monitor existing positions, and identify changing trends more efficiently than manual screening. Traders looking to stay ahead of rapid market moves can explore these signals as part of a broader research process.
Can Quantinuum reach $60? The target, derived from the average of 11 recent analyst price targets, sits about 78% above the current price and implies a substantial recovery from the stock's deep drawdown. Support comes from a strong cash position, rapid revenue growth from a small base, notable hardware achievements, and government backing. Against that, heavy losses, commercialization uncertainty, aggressive downward target revisions, and weak technical structure are meaningful obstacles. The wide $50-to-$80 analyst range underscores genuine disagreement about timing. The target is best understood as a 12-month aspiration contingent on accelerating adoption, not a near-term certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.